Robert W. Baird Issues Pessimistic Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) had its price target decreased by Robert W. Baird from $13.00 to $10.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s target price points to a potential upside of 344.44% from the company’s current […]

Leave a Reply

Your email address will not be published.

Previous post CrowdStrike (NASDAQ:CRWD) Upgraded at BTIG Research
Next post Dragonfly Energy (NASDAQ:DFLI) Lowered to Neutral Rating by Alliance Global Partners